Author: Zacks Small Cap Research

1474849505158490 / 576 POSTS
Biotricity (OTC:BTCY), a medical device company located in Redwood City, CA, is developing products focused on improving monitoring and treatment of chronic diseases.  The company’s flagship product, Bioflux, is a mobile cardiac telemetry (MCT) devic ...
By Steven Ralston, CFA NASDAQ:DSKESUMMARY OF RECENT EVENTSOn January 2, 2018, Daseke Inc. (NASDAQ:DSKE) announced that Belmont Enterprises (a truckload carrier dedicated to hauling residential glass) merged into Daseke’s SPD subsidiary (Smokey Point ...
By Brian Marckx, CFANASDAQ:EYEGEarlier this month EyeGate (NASDAQ:EYEG) announced top-line results of its phase IIb study evaluating the safety and efficacy of EGP-437 in patients which underwent cataract surgery with implantation of a monofocal post ...
By David Bautz, PhDNASDAQ:NBIX Business UpdateOpicapone NDA to be Filed in 1H19On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 foll ...
By Brian Marckx, CFANASDAQ:SBOT Q1 2018 Financial ResultsStellar (NASDAQ:SBOT) reported financial results for their fiscal 2018 first quarter ending December 31, 2017.  Revenue continues at relatively very low levels, reflecting the conclusion o ...
By David Bautz, PhDNASDAQ:OPNTBusiness UpdateOpiant to Develop OPNT003, An Improved Opioid AntagonistOn February 12, 2018, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced the development of OPNT003, a long-lasting opioid overdose treatment. OPNT ...
OTC:GTBCThe soaring valuation and perceived potential of both cryptocurrency and blockchain technology have garnered substantial attention. Bitcoin was introduced in 2009 as a decentralized digital currency. Since then, other cryptocurrencies have em ...
By Lisa ThompsonNYSE:INUVInuvo (NYSE:INUV) reported a strong Q4, which evidenced improving margins and accelerating revenues. Even more auspicious were its January results that showed a year over year increase in revenues of 37%, or 22% organically ( ...
By Steven Ralston, CFATSX:WML.VExecutive Summary• Management’s focus is migrating from the acquisition of lithium concessions to the development of its portfolio of lithium brine properties o The 2018 evaluation program is targeting the properties at ...
By David Bautz, PhDNASDAQ:MNOVAdditional Positive Data Presented for MN-166 in MSOn February 1, 2018, MediciNova, Inc. (NASDAQ:MNOV) announced the presentation of additional positive data from the SPRINT-MS clinical trial of MN-166 (ibudilast) in pat ...
1474849505158490 / 576 POSTS